by Raynovich Rod | Jan 7, 2015 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
2015: Another Good Year Unless “Something Happens” Life Science stocks had another big year in 2014 up 48% tracking gains for the overall healthcare sector up 35%. Over 10 years the return is 300%! The move up was not a straight line as there were two...
by Raynovich Rod | Jan 1, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Wishing you all a Happy and Prosperous New Year! Biotech stocks were up 47% in 2014. In 2014 the first quarter was the most volatile. Sign up now to receive all of our market and portfolio updates. In December we posted updates on our Rayno Life Science Portfolios:...
by Raynovich Rod | Dec 29, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Many Big Winners Are Among Rayno Diagnostics and Tools Stocks in 2014 Abaxis (ABAX) up 46% A major “Point of Care” (POC) Dx Player in veterinary and human markets. Exact Sciences (EXAS) up 135% An emerging Dx player with non-invasive, DNA based test for...
by Raynovich Rod | Nov 26, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
NASDAQ leads -up 0.6% to 4787 The October correction of ~7% was a “headfake” as macro events scared many investor away Technology and Healthcare Stocks Lead The Way The healthcare SPDR (XLV) is up 24.5% YTD and the technology SPDR (XLK) is up 18% YTD....
by Raynovich Rod | Nov 17, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update November 18 : NASDAQ 4702 up 0.67%, IBB at 295.25up 2.22% Recent Small Cap picks: CLDX 17.72 off 2.9% with profit taking.Very choppy trade. FCSC 2.67 flat little action, despite Press Release on amputee treatment. Foundation Medicine (FMI) at $25.86 up 2.67%....
by Raynovich Rod | Oct 31, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Investors Whipsawed By V-Shaped Rally NASDAQ at New Highs 4631 DOW at New Highs 17,390 Investors got what was forecasted-a volatile October that moved from fear to greed in two weeks! The market was buffeted by the Ebola scare, macro analysts decrying easy money from...
by Raynovich Rod | Oct 20, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Life Science ETF's and Mutual Funds
Biotechs Continue To Lead The Market NASDAQ registered its third day of gains up 2.38% for the period and life science stocks followed. The NAZ is now up 3.34% YTD. Biotech stocks are way ahead of the market YTD with our top ETF pick (FBT) up 31% YTD and 3.66% over...
by Raynovich Rod | Oct 16, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
11/15/14 Speculative Small Cap Stocks-Stay Away Unless Your Are A Trader Nice profits were booked on our recent small cap picks but today the sell-off was “pronounced”: Celldex (CLDX) was down 21% to $13.10 after hitting a high near $18 on October 31....
by Raynovich Rod | Oct 1, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
10/3 Jobs Report Clears Path for Q4 Rally 3:30P EDT A more optimistic view of the economy was triggered by a steady gain in jobs with 248k added in August and unemployment dropping below 6% to 5.9%. But average hourly wages fell in September keeping wage growth...
by Raynovich Rod | Aug 29, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Life Science ETF's and Mutual Funds
As we move into a heavier trading period watch your portfolio for changes as volume picks up. Here are some of our long term portfolio winners where you can take profits: Exact Sciences (EXAS) short squeeze took it to $22. Illumina (ILMN) triple to at $180. Here are a...
